Literature DB >> 23565852

Striatal glutamate induces retrograde excitotoxicity and neuronal degeneration of intralaminar thalamic nuclei: their potential relevance for Parkinson's disease.

Ingrid Morales1, Magdalena Sabate, Manuel Rodriguez.   

Abstract

An over-stimulation of nigral glutamate (GLU) receptors has been proposed as a cause of the progression of the dopamine (DA) cell degeneration (excitotoxicity) which characterizes Parkinson's disease. The possible toxic action of striatal GLU (retrograde excitotoxicity) on these cells, and on other neurons which innervate the striatum and which also degenerate in Parkinson's disease (thalamostriatal cells of the intralaminar thalamic nuclei), is still practically unexplored. The retrograde excitotoxicity of striatal GLU on DAergic mesostriatal and GLUergic thalamostriatal cells was tested here by studying these cells 6 weeks after striatal perfusion of GLU by reverse microdialysis. GLU perfusion induced the striatal denervation of thalamic inputs (as revealed by vesicular glutamate transporter 2) and the remote degeneration of intralaminar neurons. In both centres, these effects were accompanied by microglial activation. Similar responses were not observed for nigrostriatal neurons, which showed no dopaminergic striatal denervation, no microglial activation in the substantia nigra and no changes in the number of dopaminergic cells in the substantia nigra. The inhibition of DAergic transmission increased the extrasynaptic GLU levels in the striatum (evaluated by microdialysis), an effect observed after the local administration of agonists and antagonists of DAergic transmission, and after the peripheral administration of levodopa (which increased the DA and decreased the GLU levels in the striatum of rats with an experimental DAergic denervation of this centre). The data presented show that striatal GLU induced a retrograde excitotoxicity which did not affect all striatal inputs in the same way and which could be involved in the cell degeneration of the intralaminar nuclei of the thalamus generally observed in Parkinson's disease.
© 2013 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  Parkinson's disease; glutamate; intralaminar thalamic nuclei; retrograde excitotoxicity; striatum; substantia nigra

Mesh:

Substances:

Year:  2013        PMID: 23565852     DOI: 10.1111/ejn.12205

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  13 in total

1.  The functional connectivity of intralaminar thalamic nuclei in the human basal ganglia.

Authors:  Clara Rodriguez-Sabate; Catalina Llanos; Ingrid Morales; Roberto Garcia-Alvarez; Magdalena Sabate; Manuel Rodriguez
Journal:  Hum Brain Mapp       Date:  2014-11-27       Impact factor: 5.038

2.  Ceftriaxone Protects Astrocytes from MPP(+) via Suppression of NF-κB/JNK/c-Jun Signaling.

Authors:  Yunlong Zhang; Xiuping Zhang; Shaogang Qu
Journal:  Mol Neurobiol       Date:  2014-08-12       Impact factor: 5.590

3.  Consequences of developmental exposure to concentrated ambient ultrafine particle air pollution combined with the adult paraquat and maneb model of the Parkinson's disease phenotype in male mice.

Authors:  Joshua L Allen; Xiufang Liu; Douglas Weston; Katherine Conrad; Günter Oberdörster; Deborah A Cory-Slechta
Journal:  Neurotoxicology       Date:  2014-01-30       Impact factor: 4.294

Review 4.  Parkinson's disease as a result of aging.

Authors:  Manuel Rodriguez; Clara Rodriguez-Sabate; Ingrid Morales; Alberto Sanchez; Magdalena Sabate
Journal:  Aging Cell       Date:  2015-02-09       Impact factor: 9.304

5.  Peripheral vagus nerve stimulation significantly affects lipid composition and protein secondary structure within dopamine-related brain regions in rats.

Authors:  Artur Dawid Surowka; Anna Krygowska-Wajs; Agata Ziomber; Piotr Thor; Adrian Andrzej Chrobak; Magdalena Szczerbowska-Boruchowska
Journal:  Neuromolecular Med       Date:  2015-04-19       Impact factor: 3.843

Review 6.  The degeneration and replacement of dopamine cells in Parkinson's disease: the role of aging.

Authors:  Manuel Rodriguez; Ingrid Morales; Clara Rodriguez-Sabate; Alberto Sanchez; Rafael Castro; Jose Miguel Brito; Magdalena Sabate
Journal:  Front Neuroanat       Date:  2014-08-07       Impact factor: 3.856

Review 7.  The Rationale for Exercise in the Management of Pain in Parkinson's Disease.

Authors:  Natalie E Allen; Niamh Moloney; Vanessa van Vliet; Colleen G Canning
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

8.  Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson's disease model.

Authors:  Yunlong Zhang; Xiaoliang He; Xingjun Meng; Xiaojuan Wu; Huichun Tong; Xiuping Zhang; Shaogang Qu
Journal:  Cell Death Dis       Date:  2017-02-02       Impact factor: 8.469

9.  Earliest Mechanisms of Dopaminergic Neurons Sufferance in a Novel Slow Progressing Ex Vivo Model of Parkinson Disease in Rat Organotypic Cultures of Substantia Nigra.

Authors:  Matteo Dal Ben; Rosario Bongiovanni; Simone Tuniz; Emanuela Fioriti; Claudio Tiribelli; Rita Moretti; Silvia Gazzin
Journal:  Int J Mol Sci       Date:  2019-05-06       Impact factor: 5.923

10.  Striatal astrocytes engulf dopaminergic debris in Parkinson's disease: A study in an animal model.

Authors:  Ingrid Morales; Alberto Sanchez; Clara Rodriguez-Sabate; Manuel Rodriguez
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.